| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/19/2013 | EP2603523A1 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| 06/19/2013 | EP2603521A2 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| 06/19/2013 | EP2603520A2 Erythrocyte-binding therapeutics |
| 06/19/2013 | EP2603239A2 Neuropilin as a biomarker for bevacizumab combination therapies |
| 06/19/2013 | EP2603237A2 Anti-hemagglutinin antibody compositions and methods of use thereof |
| 06/19/2013 | EP2603236A1 Anti-syndecan-4 antibodies |
| 06/19/2013 | EP2603235A1 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| 06/19/2013 | EP2603234A1 Method for reducing dna impurities in viral compositions |
| 06/19/2013 | EP2603233A1 Vaccine engineering |
| 06/19/2013 | EP2603224A1 Methods and compositions for preventing a condition |
| 06/19/2013 | EP2603223A1 Recombinant tumor vaccine and method of producing such vaccine |
| 06/19/2013 | EP2603100A2 Dry storage stabilizing composition for biological materials |
| 06/19/2013 | CN1798834B Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survivial of transplanted hematopoietic stem cell, human monoclon |
| 06/19/2013 | CN103168104A Anti-tumor antigen antibodies and methods of use |
| 06/19/2013 | CN103168049A Anti-tenascin-c a2 antibodies and methods of use |
| 06/19/2013 | CN103167881A Methods and compositions for inhibiting HIV transmission |
| 06/19/2013 | CN103167880A Inactivated varicella zoster virus vaccines, methods of production, and uses thereof |
| 06/19/2013 | CN103167879A Dual variable domain immunoglobulins and uses thereof |
| 06/19/2013 | CN103167870A Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| 06/19/2013 | CN103160555A Culture medium, culture method and application of high-yield exotoxin of clostridium perfringens |
| 06/19/2013 | CN103160530A Fusion gene and applications thereof |
| 06/19/2013 | CN103160519A Staphylococcus aureus enterotoxin B (SEB) immune preparation and its preparation method and use |
| 06/19/2013 | CN103160477A Method for improving Japanese encephalitis virus titer |
| 06/19/2013 | CN103160475A Enterovirus 71 type viral strain, its application, vaccine and preparation method |
| 06/19/2013 | CN103160474A Enterovirus 71 type virus strain, vaccine, animal model establishment method |
| 06/19/2013 | CN103160473A Composition for recovering measles virus, and kit, purpose and method thereof |
| 06/19/2013 | CN103159859A Sendai virus antigen peptide composition and application thereof in detecting Sendai virus infection |
| 06/19/2013 | CN103159858A Swine fever branch peptide and application thereof |
| 06/19/2013 | CN103159855A Fusion protein, use thereof, and anti-malarial vaccine and antibody thereof |
| 06/19/2013 | CN103159853A Completely humanized genetic engineering fragment antigen binding (Fab) antibody against hepatitis C virus core antigen, preparation method thereof and application |
| 06/19/2013 | CN103159834A Sendai virus antigen peptide and application thereof in detecting Sendai virus infection |
| 06/19/2013 | CN103159833A Sendai virus antigen peptide and application thereof in detecting Sendai virus infection |
| 06/19/2013 | CN103157109A CD146 and antibody diagnosis thereof, and application in treating triple negative breast cancer |
| 06/19/2013 | CN103157108A An immunomodulator composition, and a pharmaceutical composition and applications thereof |
| 06/19/2013 | CN103157107A Chicken Marek's disease vaccine produced by using continuous passage cell line and production method |
| 06/19/2013 | CN103157106A Method for preparing porcine parvovirus inactivated vaccines |
| 06/19/2013 | CN103157105A Method for preparing swine fever live vaccines |
| 06/19/2013 | CN103157104A Sodium thiosulfate diluent of swine fever vaccine |
| 06/19/2013 | CN103157103A Functional influenza virus-like particles (vlps) |
| 06/19/2013 | CN103157102A Method for preparing duck hemorrhagic ovaritis inactivated vaccines |
| 06/19/2013 | CN103157101A Combined inactivate vaccine for haemophilus parasuis disease and streptococcus suis disease and preparation method for same |
| 06/19/2013 | CN103157100A hemophilus parasuis disease, swine streptococcosis bivalent inactivated vaccine and preparation method thereof |
| 06/19/2013 | CN102775478B Foot and mouth disease virus antigen peptide and vaccine |
| 06/19/2013 | CN102690789B Hybridoma cell strain secreting tetanus exotoxin monoclonal antibody, monoclonal antibody prepared by same, Fab antibody and application |
| 06/19/2013 | CN102533797B Preparation method for recombinant coxsackie virus A16 like particle and applications thereof |
| 06/19/2013 | CN102319440B Preparation method of porcine parvovirus genetic engineering vaccine |
| 06/19/2013 | CN102257138B Tumor antigen peptide and use thereof |
| 06/19/2013 | CN102250247B Bispecific antibody to VEGF/ANG2 and application thereof |
| 06/19/2013 | CN102240399B Application of siniperca chuatsi ISKNV (Infectious Spleen and Kidney Necrosis Virus) ORF093 protein |
| 06/19/2013 | CN102127167B Whole human TNF alpha (tumor necrosis factor alpha) monoclonal antibody and preparation and application thereof |
| 06/19/2013 | CN102065894B Antibody bound synthetic vesicle containing active agent molecules |
| 06/19/2013 | CN101914134B Linear epitope minimum motif peptide of human papilloma virus type 58 E7 protein |
| 06/19/2013 | CN101874041B Modified antibody constant region |
| 06/19/2013 | CN101838611B Recombinant plasmodium for expressing exogenous gene and application thereof |
| 06/19/2013 | CN101747435B Monoclonal antibody (hybrid tumor) for neutralizing CYR61 and applications thereof |
| 06/19/2013 | CN101687923B ED-A antigen of fibrinogen associated with the neovasculature of tumour metastases |
| 06/19/2013 | CN101678082B Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies |
| 06/19/2013 | CN101588816B High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
| 06/19/2013 | CN101580538B WT1-origin HLA-DR-binding antigen peptide |
| 06/19/2013 | CN101557821B Conjugates of plasmodium falciparum surface proteins as malaria vaccines |
| 06/19/2013 | CN101460519B Human binding molecules having killing activity against staphylococci and uses thereof |
| 06/19/2013 | CN101426528B Methods of using antibodies against human il-22 |
| 06/19/2013 | CN101370831B Methods and compositions for treating allergic diseases |
| 06/19/2013 | CN101353373B Synthetic peptide vaccines for foot-and-mouth disease |
| 06/19/2013 | CN101318016B Multivalent human-bovine rotavirus vaccine |
| 06/19/2013 | CN101316930B T-cell adhesion molecule and antibody directed against the molecule |
| 06/19/2013 | CN101233155B 人抗表皮生长因子受体抗体 Human anti-epidermal growth factor receptor antibody |
| 06/19/2013 | CN101213204B 丙型肝炎病毒核酸疫苗 Hepatitis C virus DNA vaccine |
| 06/19/2013 | CN101001869B Carcinoembryonic antigen fusions and uses thereof |
| 06/18/2013 | US8466268 Lactobacillus sp. JNU2116 with antimutagenic activity |
| 06/18/2013 | US8466263 Carbonic anhydrase IX (G250) anitbodies |
| 06/18/2013 | US8466262 Variable region sequences of IL-31 monoclonal antibodies and methods of use |
| 06/18/2013 | US8466261 Therapeutic using a bispecific antibody |
| 06/18/2013 | US8466259 Adjuvants |
| 06/18/2013 | US8466116 Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| 06/18/2013 | US8465945 Method for production and use of mite group 1 proteins |
| 06/18/2013 | US8465756 Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy |
| 06/18/2013 | US8465755 Recombinant bacterium capable of eliciting an immune response against enteric pathogens |
| 06/18/2013 | US8465754 Bordetella parapertussis whole-cell vaccine composition |
| 06/18/2013 | US8465753 Combination vaccines against Mycobacterium sp. and methods of using the same |
| 06/18/2013 | US8465752 Treatment of renal hypertension or carotid sinus syndrome with adventitial pharmaceutical sympathetic denervation or neuromodulation |
| 06/18/2013 | US8465751 Cna—B domain antigens in vaccines against gram positive bacteria |
| 06/18/2013 | US8465750 Staphylococcus aureus proteins and nucleic acids |
| 06/18/2013 | US8465749 Polysaccharide-protein conjugate vaccines |
| 06/18/2013 | US8465748 Vaccine compositions and methods containing an immunogen derived from equine arteritis virus |
| 06/18/2013 | US8465747 Identification, optimization and use of cryptic HLA-B7 epitopes for immunotherapy |
| 06/18/2013 | US8465746 Compositions and methods for treatment, research and therapeutic applications for malaria |
| 06/18/2013 | US8465745 Chimeric antigens for eliciting an immune response |
| 06/18/2013 | US8465744 Method of treating inflammation by administering human IL-1B antibodies |
| 06/18/2013 | US8465743 Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| 06/18/2013 | US8465742 Anti-cobra toxin antibody fragments and method of producing a VHH library |
| 06/18/2013 | US8465741 Antibodies and methods for making and using them |
| 06/18/2013 | US8465740 Regulatory T cell mediator proteins and uses thereof |
| 06/18/2013 | US8465739 Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| 06/18/2013 | US8465738 Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics |
| 06/18/2013 | US8465737 Three-dimensional structure of complement receptor type 2 and uses thereof |
| 06/18/2013 | CA2635692C Human anti-il-23 antibodies, compositions, methods and uses |
| 06/18/2013 | CA2561245C Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof |
| 06/18/2013 | CA2554635C Compounds, compositions containing such compounds and methods of treatment of autoimmune diseases using such compounds |
| 06/18/2013 | CA2513701C Dimerized peptide |